- Company
- Dividend payout for Pfizer is 12.48 million won
- by Chon, Seung-Hyun Apr 15, 2022 06:03am
- Pfizer Pharmaceutical Korea performed better last year with sales of the COVID-19 vaccine, but its dividend was only 12.48 million won. Regardless of the sharp rise in performance, the dividend payout ratio was only 0.01%, allocating 20% of the capital of preferred stocks. It has adhered to a unique dividend policy that distributes 12.48 million
- Company
- Acromegaly drug ‘Somavert’ lands in ‘Big 5’ hospitals
- by Eo, Yun-Ho Apr 15, 2022 06:03am
- The new acromegaly drug ‘Somavert’ may now be prescribed at general hospitals in Korea. According to industry sources, Pfizer Korea’s Somavert (pegvisomant) has passed the review of Drug Committees at the ‘Big 5’ tertiary hospitals in Korea including the Samsung Medical Center, Seoul National University Hospital, Seoul St.Mary’s Hos
- Company
- Artiva expands contract to develop dell therapy with MSD
- by Eo, Yun-Ho Apr 15, 2022 06:03am
- GC Pharma affiliate Artiva Biotheraputics announced on the 12th that it has signed a contract with MSD to expand the development of natural killing (NK) cell therapy. Artiva was established in 2019 by GC CELL and GC LABTECH in San Diego, USA. Under the contract, the two companies will promote joint research on anticancer drugs that combine NK
- Company
- Somavert for terminal hypertrophy can be prescribed at Big 5
- by Eo, Yun-Ho Apr 14, 2022 05:56am
- Somavert, a new drug for terminal hypertrophy, can be prescribed at a general hospital. According to related industries, Pfizer Korea's Somavert has currently passed DC of the Big 5 higher-level medical institutions such as Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, AMC, and Sinchon Severance Hospit
- Company
- “NOAC Eliquis is safe for use in high-risk groups”
- by Apr 13, 2022 06:02am
- The bleeding safety of the novel oral anticoagulant (NOAC) ‘Eliquis (apixaban)’ was reaffirmed through clinical practice guidelines of major academic societies. On the 12th, BMS Korea and Pfizer Korea announced that they have hosted a ‘VMC Master of Masters Webinar’ on the 11th to share the latest advances in preventive therapies for
- Company
- Propecia is sold in a new package
- by Apr 13, 2022 06:02am
- Organon Korea announced on the 11th that it will introduce a new package of the oral male hair loss treatment Propecia (Finasteride). As for the new package, it applied CI of Organon Korea company. Propecia, which has been sold by MSD Korea for more than 20 years since its launch in Korea in 2000, was officially launched and relocated by Orga
- Company
- KRPIA BOD meets Oh Chang-hyun, the new head
- by Eo, Yun-Ho Apr 12, 2022 06:05am
- KRPIA BOD will hold its first face-to-face meeting with Oh Chang-hyun, director of the MOHW's insurance pharmaceutical dept. According to related industries, KRPIA Board of Director (BOD) will hold a meeting with Oh Chang-hyun, the new manager, and members of the MOHW's Insurance and Pharmaceutical Affairs on the 15th. The meeting is expec
- Company
- No. of employees decline sharply due to restructuring/reorgs
- by Apr 12, 2022 06:04am
- The number of employees at multinational pharmaceutical companies has declined sharply due to their active restructuring and reorganizations. Over 200 employees have been laid off in just 4 companies - Roche Korea, Lilly Korea, Sanofi-Aventis Korea, and Zuellig Pharma Korea. According to the Financial Supervisory Service, the number of em
- Company
- Lutathera’s partner ‘LysaKare’ may be prescribed at GHs
- by Eo, Yun-Ho Apr 11, 2022 05:58am
- ‘LysaKare’, the drug concomitantly used with the neuroendocrine tumor treatment ‘Latathera’ may soon be prescribed at general hospitals. According to industry sources, Novartis Korea’s ‘LysaKare (L-arginine hcl/L-lysine hcl) has passed the drug committee (DC) reviews at 3 of the Big 5 general hospitals &8211; Samsung Medical Center
- Company
- HK inno.N's K-CAB has ended Phase 1 in US
- by Kim, Jin-Gu Apr 11, 2022 05:58am
- HK inno.N announced on the 7th that its flagship drug, "K-CAB (Tegoprazan), has successfully ended phase 1 clinical trials in the U.S., a treatment for gastroesophageal reflux disease. The clinical trial was conducted on 30 healthy adults with random assignment, double blinding, placebo control, and repeated administration. K-CAB 25 mg, 50
